NCT03480971 2024-11-20
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
Matrix Biomed, Inc.
Phase 2 Recruiting
Clinical Trials
11 trialsNCT05966194 2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2 Recruiting
NCT03515538 2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2 Completed
NCT04046250 2023-08-25
TK112690
Tosk, Inc.
Phase 2 Completed
NCT05669521 2023-08-14
Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690
Tosk, Inc.
Phase 2 Unknown
NCT02606994 2019-02-06
TPvsM
Oral Defense, LLC
Phase 2 Terminated
NCT02324335 2019-01-16
Brilacidin
Innovation Pharmaceuticals, Inc.
Phase 2 Completed
NCT02885376 2018-12-21
Study of Dentoxol® Mouthrinse for Oral Mucositis
Ingalfarma SpA
Phase 2 Completed
NCT01554254 2016-08-31
Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation
Tarix Pharmaceuticals
Phase 2 Withdrawn
NCT01882387 2016-08-31
Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation
Tarix Pharmaceuticals
Phase 2 Withdrawn
NCT00230191 2007-01-15
Safety and Efficacy of RK0202 in Oral Mucositis
RxKinetix
Phase 2 Completed